Core Viewpoint - The company reported its third-quarter financial results for 2025, highlighting a decline in revenue in certain segments while showing growth in others, particularly in the cosmetics sector. The overall financial health remains stable with significant developments in product offerings and market expansion efforts [19]. Financial Performance - For the first nine months of 2025, the company achieved a revenue of 2.597 billion yuan and a net profit attributable to the parent company of 142 million yuan [7]. - The total assets as of September 30, 2025, were 5.831 billion yuan, with net assets attributable to the parent company amounting to 4.187 billion yuan [7]. Segment Performance Cosmetics Segment - The cosmetics segment generated a revenue of 1.569 billion yuan for the first nine months of 2025, representing a year-on-year decline of 8.17%, with a gross margin of 61.24% [7]. - The Yilian brand saw a revenue increase of 19.50%, totaling 786 million yuan, with the spray product line achieving a revenue of 664 million yuan, up 28% [7]. - The Kemi brand experienced significant growth, with a revenue of 77.19 million yuan, showing a quarter-on-quarter increase of 138% in the third quarter [7]. Pharmaceutical Segment - The pharmaceutical segment reported a revenue of 305 million yuan, down 17.46% year-on-year, with a gross margin of 52.27% [8]. - The company developed over 200 new clients across hospital and OTC channels, with 70 new medical institutions added [8]. Raw Materials and Additives Segment - The raw materials and additives segment achieved a revenue of 276 million yuan, reflecting an increase of 11.19% year-on-year, with a gross margin of 40.26% [8]. - The sales volume of pharmaceutical-grade raw materials increased by 107.75% year-on-year [8]. Price Changes Product Prices - The average selling price of skincare products increased by 5.29% year-on-year due to a higher sales proportion of premium products [19]. Raw Material Prices - The average procurement price of packaging materials rose by 6.94% year-on-year, while the price of moisturizing agents decreased by 21.20% year-on-year [20][21]. - The average procurement price of active ingredients decreased by 1.45% year-on-year, while emulsifiers saw a price drop of 3.70% year-on-year [23][26]. Upcoming Events - The company will hold a performance briefing on November 3, 2025, to discuss the third-quarter results and address investor inquiries [12][14].

Core Insights - The company is facing a deep crisis during its transformation period, with financial results showing a decline in revenue and net profit, indicating a struggle with dual weak business segments and cash flow issues [1] - The cosmetics segment, which accounts for over 60% of revenue, is experiencing significant challenges, with reliance on a single product leading to an imbalanced brand portfolio [2] - The strategic transition towards a dual business model of pharmaceuticals and cosmetics is hindered by slow innovation and cash flow deterioration, raising concerns about the company's market competitiveness [3] - To overcome its challenges, the company needs to strengthen its core competencies, innovate in product development, and optimize capital efficiency [4] Financial Performance - Revenue for Q1 2025 was 876 million yuan, a year-on-year decline of 1.63% [1] - Net profit attributable to shareholders was 51 million yuan, down 14.10% year-on-year [1] Cosmetics Business Challenges - The cosmetics segment's over-reliance on a single bestselling product has led to a structural imbalance, with other brands experiencing significant revenue declines [2] - High sales expenses have not translated into sustainable growth, resulting in increased accounts receivable and inventory issues [2] - Online sales growth is lagging behind industry averages, while offline channels are suffering from reduced foot traffic [2] Strategic Transition Issues - The pharmaceutical segment's revenue has slightly decreased, and new product trials have shown limited success [3] - The company's claims of integrating AI and data into its operations remain largely conceptual, with significant challenges in product line management and innovation [3] - Cash flow issues are exacerbated by rising accounts receivable and shortened accounts payable cycles, indicating weakened bargaining power [3] Recommendations for Improvement - The company must solidify its technological barriers in the cosmetics sector and innovate active ingredients to reduce reliance on bestsellers [4] - Accelerating the research and development of pharmaceutical products and genuinely integrating AI into product development processes is crucial [4] - Improving capital efficiency and focusing on strategic initiatives rather than blind expansion is necessary to regain market share [4]